Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial

被引：3
|
作者：
Sugarman, Jeremy [1 ,2 ]
Donnell, Deborah J. [3 ]
Hanscom, Brett [3 ]
McCauley, Marybeth [4 ]
Grinsztejn, Beatriz [5 ]
Landovitz, Raphael J. [6 ]
机构：
[1] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[3] Fred Hutchison Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[4] HIV Prevent Trials Network Leadership & Operat Ct, Washington, DC USA
[5] Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil
[6] UCLA, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA
来源：
LANCET HIV | 2021年 / 8卷 / 11期
基金：
美国国家卫生研究院;
关键词：
PROTECTS MACAQUES; CABOTEGRAVIR;
D O I：
10.1016/S2352-3018(21)00153-3
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Two multinational clinical trials have shown safety and efficacy of long-acting injectable cabotegravir for HIV preexposure prophylaxis (PrEP). These results will alter the landscape of HIV prevention and related research. Nevertheless, designing and conducting this research involved several ethical issues. This Viewpoint describes how we managed ethical issues over the duration of one of these trials (HPTN 083). Specifically, we discuss the rationale for pursuing a long-acting injectable agent in the presence of effective oral PrEP, trial design choices, site selection and local standards of prevention, data monitoring and early stopping, effects of the COVID-19 pandemic, post-trial access, and assessment of long-term safety.
引用
收藏
页码：E723 / E728
页数：6
相关论文
共 50 条
  • [1] Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
    Marzinke, Mark A.
    Hanscom, Brett
    Wang, Zhe
    Safren, Steven A.
    Psaros, Christina
    Donnell, Deborah
    Richardson, Paul A.
    Sullivan, Philip
    Eshleman, Susan H.
    Jennings, Andrea
    Feliciano, Kailazarid Gomez
    Jalil, Emilia
    Coutinho, Carolina
    Cardozo, Nadir
    Maia, Bernardo
    Khan, Taimur
    Singh, Yashna
    Middelkoop, Keren
    Franks, Julie
    Valencia, Javier
    Sanchez, Naiymah
    Lucas, Jonathan
    Rooney, James F.
    Rinehart, Alex R.
    Ford, Susan
    Adeyeye, Adeola
    Cohen, Myron S.
    McCauley, Marybeth
    Landovitz, Raphael J.
    Grinsztejn, Beatriz
    LANCET HIV, 2023, 10 (11): : E703 - E712
  • [2] Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis
    Prather, Caitlin
    Jeon, Chaeok
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (21) : 1898 - 1905
  • [3] A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Pre-Exposure Prophylaxis for HIV Prevention
    Pilgrim, Nanlesta A.
    Evans, Tammeka M.
    Czarnogorski, Maggie
    HEALTH PROMOTION PRACTICE, 2022, 23 (06) : 912 - 915
  • [4] HPTN 083 interim results: Efficacy of pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations
    Grinsztejn, B.
    Donnell, D.
    Clement, M.
    Hanscom, B.
    Cottle, L.
    Coelho, L.
    Cabello, R.
    Chariyalestak, S.
    Dunne, E.
    Frank, I.
    Gaur, A.
    Gonzalez, P.
    Ha, T. V.
    Hinojosa, J.
    Kallas, E.
    Kelley, C.
    Losso, M.
    Madruga, J. Valdez
    Middelkoop, K.
    Phanuphak, N.
    Gallardo, J.
    Santos, B.
    Sued, O.
    Huanami, J. Valencia
    Hucks-Ortiz, C.
    Cardozo, N.
    Monteiro, L.
    Promjantuek, K.
    Mvula, X.
    Jones, D.
    Eshleman, S.
    Blanchette, C.
    Lucas, J.
    Scott, H.
    Fields, S.
    Gomez-Feliciano, K.
    Jennings, A.
    Rooney, J.
    Spreen, W.
    Margolis, D.
    Rinehart, A.
    Adeyeye, A.
    Cohen, M.
    McCauley, M.
    Landovitz, R.
    Vela, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 174 - 175
  • [5] Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis
    Pike, Carey
    Rousseau, Elzette
    Bekker, Linda-Gail
    SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2023, 24 (01)
  • [6] Interrogating the promise of long-acting HIV pre-exposure prophylaxis
    Pike, Carey
    Bekker, Linda-Gail
    TRENDS IN MOLECULAR MEDICINE, 2023, 29 (02) : 93 - 98
  • [7] Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa
    Moyo, Enos
    Murewanhema, Grant
    Musuka, Godfrey
    Dzinamarira, Tafadzwa
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2022, 7 (08)
  • [8] Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men
    Lorraine T. Dean
    Zachary Predmore
    Alexandra Skinner
    Siena Napoleon
    Philip A. Chan
    Julia Raifman
    AIDS and Behavior, 2023, 27 : 2606 - 2616
  • [9] Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men
    Dean, Lorraine T. T.
    Predmore, Zachary
    Skinner, Alexandra
    Napoleon, Siena
    Chan, Philip A. A.
    Raifman, Julia
    AIDS AND BEHAVIOR, 2023, 27 (08) : 2606 - 2616
  • [10] Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis
    Jamieson, Lise
    Johnson, Leigh F.
    Nichols, Brooke E.
    Delany-Moretlwe, Sinead
    Hosseinipour, Mina C.
    Russell, Colin
    Meyer-Rath, Gesine
    LANCET HIV, 2022, 9 (12): : E857 - E867
12345